The positive results here were shown in newly diagnosed seropositive patients with high disease activity who were on steroids. If we looked back at the same way on other therapies employed vs. placebo in naive patients, I wonder if we would see a more or less similar trend in all other MOAs? Also, does the window of opportunity concept in early RA apply to early ILD?